The News in Depth
Biotech product and process knowledge has created the foundation for regulatory changes, but close communication and coordination between manufacturers and regulatory agencies will be necessary to realize those changes while ensuring and advancing product quality, FDA Center for Drug Evaluation and Research (CDER) Office of Biotechnology Products (OBP) Review Chief Sarah Kennett emphasized at the […]
Protein sequence variants have been generating more questions among European CMC regulators in reviewing monoclonal and recombinant product dossiers – joining process development/validation and specification setting as areas where they are often not finding what they need to complete the review.
FDA and the excipient industry are giving more thought to how the inactive ingredient database (IID) can be improved to better support the development of emerging dosage forms, including drug delivery devices such as transdermal patches, metered dose inhalers, nasal sprays, and implants.
FDA and the EU have made significant progress down the long and winding road of formalizing an agreement to rely on each other’s drug GMP inspections.
The procedures, eligibilities and goals of EMA’s accelerated access approaches for new medicines that fill unmet medical needs, including “Priority Medicines” (PRIME) and “Adaptive Pathways” (AP), have been taking more concrete shape, informed by the European agency’s growing implementation experience.
In focus are the active discussions now going on between industry and regulators on: ● the role that knowledge management can play in evolving the lifecycle quality regulatory paradigm ● how to make the agency’s inactive ingredient database (IID) as accurate and useful as possible, and ● how regulators are refining their expectations and guidance around data integrity based on their inspection experience, and what companies should be doing, in turn, to uncover, fix, and prevent data integrity problems.
August 25, 2016 | Posted in The News in Depth
| Read More »
FDA’s Office of Pharmaceutical Quality (OPQ) is sharpening its vision of how to increase the reliability and user input in its Inactive Ingredient Database (IID) to make it more beneficial to both internal and external users.
U.S. and European regulators are giving a clear message at public meetings and in their written guidance that up-front communication with the agencies about data integrity lapses that a company has uncovered is critical to maintaining trust and avoiding more serious enforcement repercussions later.
The number and depth of comments FDA received on its new draft data integrity (DI) guidance, and the dialogue the guidance has generated at recent public forums, indicate the high profile nature, dimension, and complexity of the challenges regulators face in overseeing and seeking to advance industry DI practices.
Guidances issued between April and July 2016 by FDA, UK’s Medicines and Healthcare Products Regulatory Agency (MHRA), and the World Health Organization (WHO) are providing a stronger foundation for the industry/regulator dialogue around the world on where the current gaps are in industry’s oversight of data integrity (DI) and how those gaps should be filled.
Subscribe today and get 24/7 access to the IPQ family of publications:
- “In the News” — breaking stories on our website
- “Weekly News Alert” — sent via email
- “Monthly Update” — the key CMC and GMP developments in the US, Europe and internationally
- “Special Reports” — in-depth analysis of specific, emerging issues of regulator/industry concern
- Documents and Archives — Live links to all the documents referenced in our stories and full access to IPQ’s valuable archive library
Click here for the November/December 2015 Monthly Update
IPQ is dedicated to helping advance the dialogue on evolving and harmonizing the regulation of pharmaceutical and biologic quality and manufacturing.
IPQ takes its readers from:
- ● the headlines to the forces driving them
- ● regulations and policies to their underlying intent
- ● the pieces of the puzzle to their interconnection
- ● requirements to implementation pathways
- ● random data to critical trends
- ● the sidelines to helping shape the outcome
- ● compliance problems to proactive quality tools
- ● information to intelligence
Subscribe today and get 24/7 access to the IPQ family of publications: “In the News” — breaking stories on our website; “Weekly News Alert” — sent via email; “Monthly Update” — the key CMC and GMP developments in the US, Europe and internationally; “Special Reports” — in-depth analysis of specific, emerging issues of regulator/industry concern; and Documents and Archives — live links to all the documents referenced in our stories and full access to IPQ’s valuable archive library.